Cowen and Company Lowers Omeros Corporation (OMER) to Market Perform

Cowen and Company lowered shares of Omeros Corporation (NASDAQ:OMER) from an outperform rating to a market perform rating in a report released on Thursday, November 2nd.

OMER has been the subject of several other research reports. Cantor Fitzgerald reissued a hold rating and issued a $19.00 target price (up previously from $15.00) on shares of Omeros Corporation in a research note on Thursday, August 24th. Zacks Investment Research downgraded shares of Omeros Corporation from a buy rating to a hold rating in a research note on Wednesday, October 25th. Maxim Group set a $24.00 price objective on shares of Omeros Corporation and gave the company a buy rating in a research note on Friday, October 20th. Finally, Wedbush reaffirmed an outperform rating and set a $47.00 price objective on shares of Omeros Corporation in a research note on Friday, August 18th. Two analysts have rated the stock with a sell rating, four have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Omeros Corporation has an average rating of Hold and a consensus price target of $34.14.

Shares of Omeros Corporation (NASDAQ:OMER) traded up $0.64 during mid-day trading on Thursday, reaching $18.81. 2,806,000 shares of the company traded hands, compared to its average volume of 802,264. Omeros Corporation has a 12-month low of $8.71 and a 12-month high of $27.09. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.

Omeros Corporation (NASDAQ:OMER) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.18. The firm had revenue of $21.66 million during the quarter, compared to analyst estimates of $17.82 million. During the same period in the previous year, the firm posted ($0.34) EPS. The company’s revenue for the quarter was up 91.9% compared to the same quarter last year. analysts expect that Omeros Corporation will post -1.32 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This news story was originally posted by Week Herald and is owned by of Week Herald. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international trademark & copyright laws. The correct version of this news story can be accessed at https://weekherald.com/2017/11/15/omeros-corporation-omer-rating-lowered-to-market-perform-at-cowen-and-company.html.

Several large investors have recently modified their holdings of OMER. First Interstate Bank purchased a new stake in shares of Omeros Corporation during the 3rd quarter worth about $108,000. Legal & General Group Plc grew its holdings in shares of Omeros Corporation by 7.8% during the 2nd quarter. Legal & General Group Plc now owns 10,359 shares of the biopharmaceutical company’s stock worth $208,000 after purchasing an additional 751 shares during the period. Hanseatic Management Services Inc. grew its holdings in shares of Omeros Corporation by 10,919.6% during the 3rd quarter. Hanseatic Management Services Inc. now owns 10,689 shares of the biopharmaceutical company’s stock worth $231,000 after purchasing an additional 10,592 shares during the period. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Omeros Corporation during the 3rd quarter worth about $256,000. Finally, SG Americas Securities LLC grew its holdings in shares of Omeros Corporation by 138.9% during the 3rd quarter. SG Americas Securities LLC now owns 12,154 shares of the biopharmaceutical company’s stock worth $263,000 after purchasing an additional 7,067 shares during the period. Institutional investors and hedge funds own 45.37% of the company’s stock.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Receive News & Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply